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Abstract
Purpose: To compare the short-term visual function results and safety of erythropoietin as an add-on to the
standard corticosteroid therapy in retrobulbar optic neuritis (RON).
Methods: In this prospective pilot study, adult patients with isolated RON with less than 10 days of
onset were enrolled. Patients were consecutively assigned to standard intravenous methylprednisolone
treatment either in combination with intravenous erythropoietin (20,000 units/day for three days) (group-1) or
intravenousmethylprednisolone alone (group-2). Primary outcomemeasurewas best-corrected visual acuity
(BCVA), which was assessed up to 120 days from the day the treatment was begun. Systemic evaluations
were performed during and after treatment.
Results: Sixty-two patients with RON (mean age = 26.6 ± 5.77 years; range = 18–40 years) were enrolled into
the study (group-1, 𝑛 = 35; group-2, 𝑛 = 27). BCVA three months after the treatment was 0.19 ± 0.55 logMAR
and 0.11 ± 0.32 logMAR in group-1 and group-2, respectively (95% CI: −0.61 − 0.16; 𝑃 = 0.62). Change in
BCVA after three months was 2.84 ± 3.49 logMAR in group-1 and 2.46 ± 1.40 logMAR in group-2 (95% CI:
−0.93−1.91; 𝑃 = 0.57). Pace of recovery was not significantly different between the groups. No complications
were detected among patients.
Conclusion: Intravenous erythropoietin as an add-on did not significantly improve the visual outcome in
terms of visual acuity, visual field, and contrast sensitivity compared to traditional intravenous corticosteroid.
This pilot study supports the safety profile of intravenous human recombinant erythropoietin, and it may help
formulate future investigations with a larger sample size.
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INTRODUCTION
Acute optic neuritis is an inflammatory, demyeli-
nating disorder. It is the most common optic
neuropathy affecting young adults.[1] Main patho-
logic features include microglial and T cell infil-
tration, edema, myelin breakdown, axonal and
neuronal degeneration, and astrogliosis of the
optic nerve.[2–4] Following an episode of optic
neuritis, the optic nerve undergoes atrophy.[5]
Although, in most patients, visual acuity recovers
rapidly following an episode of acute optic neuritis,
significant number of patients suffer from distur-
bances of visual functions such as best-corrected
visual acuity (BCVA), contrast sensitivity (CS), color
vision, and visual field.[5–7] In an optic neuritis
treatment trial (ONTT) study, which involved long-
term follow-up, 26% of the patients showed a
visual acuity that was lower than 20/20 in the
affected eye, and 33% showed abnormal CS and
visual field.[7] Methylprednisolone pulse therapy is
the standard treatment for acute optic neuritis.
Although it accelerates visual recovery, it does not
influence visual outcome, lesion length, or atrophy
of the optic nerve.[4, 7, 8] Furthermore, the safety
of high dose corticosteroid treatment on retinal
ganglion cell (RGC) survival is debated. An exper-
imental study on an optic neuritis model showed
that methylprednisolone increased RGC degener-
ation by inhibiting an endogenous neurotrophin-
dependent pathway.[9]
In addition to the treatment using anti-
inflammatory and immunomodulatory agents,
neuroprotection and neuroregeneration are other
intriguing treatment strategies. Erythropoietin has
shown neuroprotective and neuroregenerative
properties. Recent experimental and clinical
studies support the efficacy of erythropoietin in
various clinical optic nerve disorders including
traumatic optic neuropathy,[10, 11] ischemic optic
neuropathy,[12] toxic optic neuropathy,[13] and optic
neuritis.[14, 15] In a recent study, patients treated with
a combination of corticosteroid and erythropoietin
were found to have higher retinal nerve fiber layer
(RNFL) thickness and optic nerve diameter.[14] In
the current study, we aimed to compare different
optic nerve function parameters in patients with
isolated retrobulbar optic neuritis (RON), who were
subjected to high dose corticosteroid treatment
either in combination with erythropoietin or alone.
METHODS
This was a prospective pilot study conducted in
a tertiary university-based referral hospital. The
ethics committee of eye research center affiliated
to Rassoul Akram Hospital, Iran University of Med-
ical Sciences approved this study. The purpose of
the study and its possible outcomes and adverse
events were explained to all participants, and writ-
ten informed consents were obtained. The study
was conducted according to the tenets of Helsinki
Declaration. From November 2010 to March 2013,
patients with acute visual loss and preliminary
diagnosis of RON, who were referred from general
and neuro-ophthalmology clinics, were evaluated.
The eligibility criteria were mainly based on ONTT
[Table 1].
All patients underwent a comprehensive oph-
thalmologic evaluation, which included assess-
ment of detailed history, BCVA (with a standard
Landolt C chart in a single room), relative affer-
ent pupillary response, color vision (with Ishihara
plates), extra-ocular movements, and intra-ocular
pressure (by application tonometry), in addition to
dilated funduscopic examination (with 78 D lens)
and anterior segment examination (with slit lamp).
Diagnosis of isolated RON was confirmed by an
expert neuro-ophthalmologist.
All patients were hospitalized. Complete blood
cell count, hematocrit, aspartate transaminase
(AST), alanine transaminase (ALT), alkaline phos-
phatase, blood urea nitrogen, blood creatinine,
blood sugar, and C-reactive protein, in addition
to serum sodium, calcium, phosphorus, and mag-
nesium were evaluated. In the case of abnormal
lab data, treatment was stopped and an internal
medicine specialist was consulted.
Patients were subsequently assigned into one
of the two treatment groups after obtaining
informed consent; those receiving intravenous
human recombinant erythropoietin and methyl-
prednisolone for three successive days were
assigned to group-1 and those receiving only intra-
venous methylprednisolone for three successive
days were assigned to group-2. Patients in both
groups received oral prednisolone 1 mg/kg/day for
additional 11 days after the intravenous treatment.
All patients received 250 mg intravenous
methylprednisolone every six hours. In addition,
20,000 international units of intravenous
recombinant human erythropoietin (PDpoetin,
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Table 1. Eligibility criteria
Inclusion Criteria Exclusion Criteria
Acute visual symptoms Pregnancy
Normal optic disc and fundoscopic exam with 78 D lens Breastfeeding
Relative afferent pupillary defect Clinically definite MS
Visual field defect in the affected eye Hyperopia > 3 diopter, myopia > −5.0 diopter, irregular
astigmatism
Age range of 18 years to 40 years Elevated blood pressure (systolic > 140 mmHg, Diastolic > 90
mmHg)
No previous episodes of optic neuritis in the affected eye History of thrombi-embolic events
No previous congenital or acquired ophthalmological
morbidity hindering the visual functions
Malignancy
No previous corticosteroid or erythropoietin treatment for
optic neuritis
Seizures
No systemic disease History of collagen vascular disease
Best-corrected visual acuity ≤ 20/40 Sarcoidosis
Duration of symptoms less than 10 days Graves’ disease
Heavy cigarette smoking
History or clinical findings for severe ophthalmic diseases such
as central retinal vein occlusion
Any hereditary or acquired macular disease
History of any intraocular or keratorefractive surgery
Any abnormal findings in orbital or brain MRI suggestive of
decreased visual function
MRI, magnetic resonance imaging; MS, multiple sclerosis
Pooyesh Darou Pharmaceutical Co., Tehran, Iran)
was infused into 200 ml normal saline in group-
1. Patients in group-2 received 200 ml normal
saline per day as placebo. Systolic and diastolic
blood pressures were checked every 15 minutes
during erythropoietin infusion. The patients were
excluded from the study if they met the exclusion
criteria.
Inclusion, group assignment, and management
process were directed by an expert ophthalmolo-
gist (FP). Follow-up examinations were performed
using the same charts and instruments by a
senior ophthalmology resident (FM). Both neuro-
ophthalmologist and examiner were blind to the
treatment protocol.
Primary outcome measure was BCVA. Visual
acuity was measured by standard Landolt C acuity
chart after best spectacle correction. Color vision
was checked with 15 Ishihara plates if visual acu-
ity was 20/160 (0.9 logMAR) or better. Contrast
sensitivity (CS) was checked using a YANG vision
tester (SIFI MEDTECH group Co., Lavinaio, Italy)
at a distance of 3 m and spatial frequency of
6-cycle/degree (c/d) at 30–70 foot-lambert illumi-
nation. All visual functions were assessed before
treatment and at days 1, 2, 3, 14, 30, 60, and
120 after treatment. Visual field was evaluated
with Humphrey 750 using C-24-2 SITA-standard
strategy (target size = 3, white target) on days 0,
14, 30, 60, and 120 if BCVA was 20/200 (logMAR =
1.0) or better. Hemoglobin, hematocrit, and platelet
count were checked on days 0, 30, and 60 after
treatment.
A probability value of less than 0.05 was consid-
ered significant for all statistical tests. The indepen-
dent sample t-test was used for the comparison of
normal numeric parameters. Kaplan–Meier survival
analysis was performed to estimate time to event;
the cut-off point for BCVA was logMAR ≤ 0 and
that for CS was ≥70.[15] Statistical analyses were
carried out with the Statistical Package for Social
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Sciences (SPSS Package, version 22, IBM Corpo-
ration, Armonk, New York, USA).
RESULTS
Weevaluated 102 patients with acute isolated RON.
Thirty-five patients received corticosteroid treat-
ment in combination with erythropoietin (group-
1) and twenty-seven subjects received corticos-
teroid treatment alone (group-2). Forty cases were
excluded because they did not fulfill the inclusion
criteria or because they met the exclusion criteria
[Table 1].
The mean age of the included patients was
26.6 ± 5.77 (range = 18–40) years. Of 62 patients,
43 were female (69.35%). Time delay in treatment
(interval between the onset of symptoms and
initiation of treatment) in both groups did not differ
significantly. Demographic data are shown in Table
2.
At baseline, there was no statistically significant
difference in mean visual acuity (represented in
logMAR) between group-2 (2.35 ± 1.25) and group-
1 (2.15 ± 1.18) (P = 0.52). Three months after
treatment, BCVA of 20/20 or better (logMAR ≤ 0)
was achieved in 48 (66.1%) patients, among which
29 (71.4%) patients belonged to group-1 and 19
(59.3%) to group-2. BCVA at three months follow-
up time-point was found to be 0.11 ± 0.32 logMAR
and 0.19 ± 0.55 logMAR in group-2 and group-1 (P
= 0.51), respectively [Figure 1].
The pace of recovery was not different between
the two groups. BCVA of 20/20 or better (log MAR
≤ 0) was achieved in 34.52 days after treatment in
group-1 and in 41.12 days after treatment in group-
2 (P = 0.59). Change in BCVA after three months
was 2.84 ± 3.49 logMAR in group-1 and 2.46 ±1.40
in group-2 (P = 0.632), compared to pre-treatment
baseline values.
Baseline CS (represented in 6 C/D) was 6.85 ±
9.1 in group-1 and 6.98 ± 7.36 in group-2. Improve-
ment of CS (cut-off point > 70) was achieved
after three months in 25 (40.3%) patients with
RON, among which 18 (51.4%) patients belonged
to group-1 and 7 (25.9%) to group-2. CS was not
significantly different between the two groups. Cut-
off point of CS (> 70) improved in 73.33 days (range
= 58.13–88.53) in group-1 and in 85.71 days (range
= 61.95–109.47) in group-2 [Figure 2]. The change
in CS after three months was observed to be 65.78
Figure 1. Best-corrected visual acuity (BCVA) at different time
intervals among patients with retrobulbar optic neuritis in the
two treatment groups. IV MP, intravenous methylprednisolone;
IV MP + EPO, intravenous methylprednisolone in combination
with intravenous erythropoietin.
Figure 2. Comparison of contrast sensitivity in patients with
retrobulbar optic neuritis in the two treatment groups. IV MP,
intravenous methylprednisolone; IV MP + EPO, intravenous
methylprednisolone in combination with intravenous erythro-
poietin.
± 32.32 in group-1 and 51.09 ± 33.92 in group-2 (P
= 0.078).
Analysis of mean deviation (MD) showed insignif-
icant differences among participants in group-1
and group-2 after three months. Pattern standard
deviation (PSD) showed no significant differences
between the two groups except on day 60 (P =
0.002) [Figure 3].
Mean baseline values of color vision test were
2.3 ± 2.06 and 3.37 ± 2.72 in group-1 and group-
2 (P = 0.377), respectively. Four months after
treatment, mean color vision values of patients in
group-1 and group-2 were 11.96 ± 4.49 and 12.94 ±
2.68, respectively (P = 0.338).
There was no significant difference in the
platelet count change at days 30 and 60 after
treatment in both groups. Mean hematocrit change
in the male and female patients of group-1 and
group-2 after 30 and 60 days of treatment was
statistically insignificant. We observed transient
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Table 2. Demographics of patients with retrobulbar optic neuritis
Group-1 Group-2 P value
Age (mean ± SD; years) 25.54 ± 5.943 27.70 ± 5.587 0.14
Sex (F:M) 29 (70.7%): 12 (29.3) 25 (64.1%):14 (35.9%) 0.63
Time interval ± SD (days)* 5.91 ± 2.66 5.29 ± 2.34 0.33
*Time interval between onset of visual symptoms and starting protocol treatment
Group-1 = Combined erythropoietin and methylprednisolone treatment
Group-2 = Methylprednisolone treatment
F, female; M, male; SD, standard deviation
Figure 3. Mean deviation (MD) in patients with retrobulbar
optic neuritis in the two treatment groups. IV MP, intravenous
methylprednisolone; IV MP + EPO, intravenous methylpred-
nisolone in combination with intravenous erythropoietin.
increase in systolic blood pressure in a 35-year-
old patient during intravenous infusion of ery-
thropoietin. No further increase in blood pressure
was recorded during follow-up. During treatment
and follow-up period, no remarkable complications
were detected among patients.
DISCUSSION
In this pilot study, we have compared short-term
visual function results of intravenous methylpred-
nisolone with andwithout erythropoietin as an add-
on in patients with acute RON.
Results of ONTT showed that corticosteroids
could accelerate visual recovery.[4] However, in
about one-third of these patients, residual dis-
turbances in various aspects of visual functions,
including central visual acuity, CS, and visual field
can persist.[7] Optic neuritis is associated with
RGC loss and RNFL thinning.[16] Axonal loss in
the RNFL has consistently been demonstrated
following optic neuritis,[16] and after an episode of
optic neuritis, 74% of the patients show thinning
of RNFL, denoting axonal damage, and RGC loss
in addition to their correlation to visual function
deficit.[17] Furthermore, high dose corticosteroid
therapy possibly increases RGC apoptosis follow-
ing optic neuritis; this is an issue of concern.[5]
These findings signify permanent structural and
functional deficits in the visual system after an
episode of optic neuritis and, thus, justify the
use of neuroprotective and regenerative treatment
options.
Erythropoietin, which has long been known as
a hematopoietic cytokine, can protect neurons
from apoptosis[18–20] and show protective effects
in experimental models of mechanical optic nerve
trauma,[21] inflammation,[22, 23] cerebral and retinal
ischemia,[23] and oxidative stress,[24] in addition to
animal model of optic neuritis.[9, 25] Clinical studies
over the recent decade have also supported the
use of erythropoietin as a neuroprotective and
neuroregenerative agent in certain acquired optic
neuropathies such as traumatic,[10,11] ischemic,[12]
demyelinative, inflammatory,[14] and toxic[13] optic
neuropathies.
One study on experimental optic neuritis model
suggested that both neuronal and axonal pro-
tection, in functional and structural aspects, are
most effective when combined erythropoietin
and methylprednisolone treatment regimen was
commenced. Isolated neuronal or axonal pro-
tection, without clinical benefit, was achieved
under monotherapy with either erythropoietin or
methylprednisolone.[25, 26]
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Suhs et al demonstrated lower RNFL thin-
ning and lower values of visual evoked poten-
tial parameters in patients with optic neuritis
when they received 33,000 units/day of intra-
venous erythropoietin for three days as an add-
on therapy to methylprednisolone compared to
those who received only methylprednisolone.[14]
The aforementioned studies favored the structural
and physiological effects of erythropoietin in treat-
ing optic neuritis. However, our study could not
show a significant superior effect of the combined
intravenous treatment (erythropoietin along with
methylprednisolone) in terms of the extent and
rapidity of recovery of CS, BCVA, and visual field
parameters.
All our patients experienced partial or complete
recovery of BCVA after three months. Recovery of
CS, visual acuity, visual field, and color vision is
characteristic after an episode of optic neuritis; the
magnitude of the recovery of the aforementioned
visual functions in the current study is comparable
to other studies.[9]
Although we observed some trends that point
toward the achievement of a better visual function
in erythropoietin-treated patients, changes in func-
tional parameters were not significantly different
between the treatment groups. Furthermore, Suchs
et al also did not observe any significant difference
in visual acuity in patients who were administered
erythropoietin as an add-on to methylprednisolone
despite higher RNFL thickness in optical coherence
tomography (OCT)measurements.[14] Such discrep-
ancy may be explained at least in part by the
fact that papillomacular bundle, rather than mean
peripapillary nerve fiber layer thickness, subserves
the fovea, which is responsible for the central visual
acuity.
CS is a more sensitive visual function than visual
acuity. It remains impaired in 33% of the patients,
years after acute optic neuritis.[7]
We did assess CS, which has recently
been reported to detect even subtle visual
impairment.[15] During the final follow-up evaluation
of patients, improved CS (> 70) was observed in
25 (40.3%) patients, of whom 18 (51.4%) belonged
to group-1 and 7 (25.9%) to group-2.
The major complications that were reported
with erythropoietin include polycythemia, thrombo-
embolic events,[27] hypertensive reactions,[27] and
pure red cell aplasia.[28] We did not observe any
significant change in hematocrit, platelet count,
or any other clinical parameters that can be clas-
sified as adverse events. Blood pressure of the
participants in both groups remained stable during
the treatment period and thereafter, it did not
differ significantly between the treatment groups.
However, there was an exception. One participant
who had received combined erythropoietin and
methylprednisolone treatment experienced a mild
and transient elevation in systolic blood pressure,
which returned to baseline level after the infusion
was put on hold for 15 minutes; no further changes
were observed after restarting the infusion.
Limitations of this pilot study included relatively
small sample size and lack of randomization.
Authors cannot ignore one other possible reason
for the absence of difference between the two
groups, that is, the suppression of the neuropro-
tective effect of erythropoietin by concurrent corti-
costeroid therapy. In the future, randomized clinical
trials with larger sample size may reveal statistically
significant differences in the visual outcome after
erythropoietin treatment. For future studies, our
calculation shows that each group should have a
sample size of 37 subjects to detect a difference
of at least 0.2 logMAR and to have 80% power.
Structural data such as that obtained through OCT
could provide useful complementary data, and it
should be regarded in future studies. Furthermore,
follow-up time was short. Longer follow-up periods
are needed to justify any possible visual benefits
in long-term scales in patients with optic neuritis.
This may justify future studies with larger sample
size and different erythropoietin doses.
In conclusion, we found that adding intra-
venous human recombinant erythropoietin could
not statistically improve short-term visual function
results compared to systemic high dose methyl-
prednisolone treatment. Furthermore, this study
supports the safety profile of intravenous human
recombinant erythropoietin.
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